Wedbush reaffirmed their outperform rating on shares of Vigil Neuroscience (NASDAQ:VIGL – Free Report) in a research note released on Wednesday morning, Benzinga reports. The firm currently has a $22.00 price target on the stock.
VIGL has been the subject of several other reports. HC Wainwright reissued a buy rating and set a $24.00 target price on shares of Vigil Neuroscience in a research note on Wednesday. JMP Securities reissued a market outperform rating and set a $23.00 price objective on shares of Vigil Neuroscience in a research report on Thursday, April 18th.
View Our Latest Stock Report on VIGL
Vigil Neuroscience Stock Performance
Vigil Neuroscience (NASDAQ:VIGL – Get Free Report) last issued its quarterly earnings results on Tuesday, March 26th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.01). Equities analysts predict that Vigil Neuroscience will post -2.56 EPS for the current fiscal year.
Hedge Funds Weigh In On Vigil Neuroscience
An institutional investor recently raised its position in Vigil Neuroscience stock. PEAK6 Investments LLC raised its holdings in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL – Free Report) by 66.0% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 23,796 shares of the company’s stock after acquiring an additional 9,459 shares during the quarter. PEAK6 Investments LLC owned approximately 0.07% of Vigil Neuroscience worth $128,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 83.64% of the company’s stock.
About Vigil Neuroscience
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
Further Reading
- Five stocks we like better than Vigil Neuroscience
- Investing in Construction Stocks
- Has FMC Stock Reached Bottom? First Quarter Earnings Say Yes
- What is the Dow Jones Industrial Average (DJIA)?
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- How Can Investors Benefit From After-Hours Trading
- Generac Powers Ahead on the Electrification Mega-Trend
Receive News & Ratings for Vigil Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vigil Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.